E. Yekedüz, E. B. Köksoy, S. C. Yazgan, I. Akbıyık, S. Balli, E. Kavak, E. Kalacı, B. Dursun, Pınar Kubilay Tolunay, M. Gürbüz, H. Akbulut, A. Demirkazık, F. Çay Şenler, G. Utkan, Y. Ürün
M. Karakurt Eryılmaz, M. Karaağaç, M. Koçak, M. Korkmaz, Muzaffer Uğraklı, Engin Hendem, A. Demirkıran, M. Er, D. Çağlayan, M. Araz, H. Bozcuk, M. Artaç
ABS TRACT Objective: This study aimed to evaluate the impact of the coronavirus disease-2019 (COVID-19) pandemic on the follow-up and management of cancer patients. Material and Methods: A survey consisting of 15 questions asking whether there was a delay in follow-up or treatment of cancer during the COVID-19 pandemic was applied to the cancer patients who were admitted to our medical oncology out-patient clinic for follow-up or treatment. Results: A total of 209 cancer patients were included in this study. In 56 (26.8%) patients, there was a delay in the follow-up or treatment of cancer. The delay in cancer treatment occurred in 37 (66%) patients, and the delay in the follow-up of cancer occurred in 19 (34%) patients. The median delay in the follow-up and treatment of cancer was both 30 days (range 1-120) and (range 2-120), respectively. 12.5% of all patients who encountered delays in cancer follow-up or treatment had subsequent cancer-related complications. Also, the delay was significantly higher in quarantined patients and patients diagnosed with severe acute respiratory syndrome-coronavirus-2. In binary logistic regression analysis, living in rural areas and being quarantined due to the COVID-19 pandemic were deter-mined as independent predictors of the delay. Conclusion: The COVID-19 outbreak caused delays in the follow-up and treatment of cancer patients, and acute complications arose due to unavoidable disruptions. To prevent long-term negative consequences of delays in cancer fol-low-up and treatment, it is necessary to adapt the treatments judiciously without sacrificing patient safety and care.
{"title":"The Impact of the COVID-19 Pandemic on Follow-Up and Management of Cancer Patients","authors":"M. Karakurt Eryılmaz, M. Karaağaç, M. Koçak, M. Korkmaz, Muzaffer Uğraklı, Engin Hendem, A. Demirkıran, M. Er, D. Çağlayan, M. Araz, H. Bozcuk, M. Artaç","doi":"10.37047/jos.2021-83957","DOIUrl":"https://doi.org/10.37047/jos.2021-83957","url":null,"abstract":"ABS TRACT Objective: This study aimed to evaluate the impact of the coronavirus disease-2019 (COVID-19) pandemic on the follow-up and management of cancer patients. Material and Methods: A survey consisting of 15 questions asking whether there was a delay in follow-up or treatment of cancer during the COVID-19 pandemic was applied to the cancer patients who were admitted to our medical oncology out-patient clinic for follow-up or treatment. Results: A total of 209 cancer patients were included in this study. In 56 (26.8%) patients, there was a delay in the follow-up or treatment of cancer. The delay in cancer treatment occurred in 37 (66%) patients, and the delay in the follow-up of cancer occurred in 19 (34%) patients. The median delay in the follow-up and treatment of cancer was both 30 days (range 1-120) and (range 2-120), respectively. 12.5% of all patients who encountered delays in cancer follow-up or treatment had subsequent cancer-related complications. Also, the delay was significantly higher in quarantined patients and patients diagnosed with severe acute respiratory syndrome-coronavirus-2. In binary logistic regression analysis, living in rural areas and being quarantined due to the COVID-19 pandemic were deter-mined as independent predictors of the delay. Conclusion: The COVID-19 outbreak caused delays in the follow-up and treatment of cancer patients, and acute complications arose due to unavoidable disruptions. To prevent long-term negative consequences of delays in cancer fol-low-up and treatment, it is necessary to adapt the treatments judiciously without sacrificing patient safety and care.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69820470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
İ. Gökmen, E. Taştekin, A. Gökyer, Sezin Sayın, I. Çiçin
diagnosis and treatment, the incidence of lung cancer remains high both in Turkey and worldwide, and it is one of the leading causes of cancer-related deaths.1 When we evaluate Turkey, according to the age-standardized cancer rate in males, lung cancer occupies first place with 57.7%, and in females, it is at fifth place with 9.8%. 80% of lung cancer cases are nonsmall cell lung cancer (NSCLC), most of them are diagnosed at an advanced stage, and only 19% of patients can live for five years or longer.2 The dominant histological subtype in NSCLC is adenocarcinoma both in the world and in Turkey (47.1%).3
{"title":"Distribution Data of Epidermal Growth Factor Receptor Mutations Detected by Next-Generation Sequencing Method in Non-Small Cell Lung Cancer","authors":"İ. Gökmen, E. Taştekin, A. Gökyer, Sezin Sayın, I. Çiçin","doi":"10.37047/jos.2021-84407","DOIUrl":"https://doi.org/10.37047/jos.2021-84407","url":null,"abstract":"diagnosis and treatment, the incidence of lung cancer remains high both in Turkey and worldwide, and it is one of the leading causes of cancer-related deaths.1 When we evaluate Turkey, according to the age-standardized cancer rate in males, lung cancer occupies first place with 57.7%, and in females, it is at fifth place with 9.8%. 80% of lung cancer cases are nonsmall cell lung cancer (NSCLC), most of them are diagnosed at an advanced stage, and only 19% of patients can live for five years or longer.2 The dominant histological subtype in NSCLC is adenocarcinoma both in the world and in Turkey (47.1%).3","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69820789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yusuf Ilhan, M. Korkmaz, E. Güzel, K. Mammadova, S. S. Göksu, A. Tatlı, H. Coşkun
rare neurological complication in cancer, characterized by the rapid development of cerebellar ataxia resulting from tumor-induced autoimmunity against cerebellar Purkinje cells. It is mostly seen in gynecological cancers, breast cancer, and small cell lung cancer.1 AntiYo antibody, also known as anti-Purkinje cell cytoplasmic antibody type-1 is highly specific and the most frequently found antibody in patients with PCD. Other antibodies associated with PCD are anti-Hu, antiTr, anti-Ri, and anti-mGluR1. However, no antibodies are identified in nearly 40% of PCD patients.2-4 PCD occurs in about 0.2% of patients with malignant tumors and is characterized by cerebellar symptoms such as ataxia, vertigo, and dysarthria.5 Here, we present a case of anti-Yo-associated PCD in an ovarian cancer patient.
{"title":"Anti-Yo Associated Paraneoplastic Cerebellar Degeneration in Ovarian Cancer: A Rare Case Report","authors":"Yusuf Ilhan, M. Korkmaz, E. Güzel, K. Mammadova, S. S. Göksu, A. Tatlı, H. Coşkun","doi":"10.37047/JOS.2020-78768","DOIUrl":"https://doi.org/10.37047/JOS.2020-78768","url":null,"abstract":"rare neurological complication in cancer, characterized by the rapid development of cerebellar ataxia resulting from tumor-induced autoimmunity against cerebellar Purkinje cells. It is mostly seen in gynecological cancers, breast cancer, and small cell lung cancer.1 AntiYo antibody, also known as anti-Purkinje cell cytoplasmic antibody type-1 is highly specific and the most frequently found antibody in patients with PCD. Other antibodies associated with PCD are anti-Hu, antiTr, anti-Ri, and anti-mGluR1. However, no antibodies are identified in nearly 40% of PCD patients.2-4 PCD occurs in about 0.2% of patients with malignant tumors and is characterized by cerebellar symptoms such as ataxia, vertigo, and dysarthria.5 Here, we present a case of anti-Yo-associated PCD in an ovarian cancer patient.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"7 1","pages":"31-33"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69818986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Gürbüz, E. Akkuş, Bilgin Karaalioğlu, E. Aktaş, E. B. Köksoy, Hilal Özakıncı, S. Hayme, Y. Urun, S. Sak, A. Demirkazık, G. Utkan
EGFR is an important therapeutic target in lung adenocarcinoma.4 Oral tyrosine kinase inhibitors (TKIs) can be used in patients with driver mutations in EGFR.5 EGFR mutations were observed in ~1015% of NSCLC patients in Western populations and up to 50% in Asian populations.6,7 In a previous study, the EGFR mutation rate in adenocarcinomas was 33.9% for women and 9.4% for men in 499 cases, and the overall mutation rate was 14%.8 Also, EGFR mutations are more frequently detected in female patients and non-smokers.9
{"title":"Association Between Blood Type and Epidermal Growth Factor Receptor Mutation Positivity in Lung Adenocarcinoma Patients","authors":"M. Gürbüz, E. Akkuş, Bilgin Karaalioğlu, E. Aktaş, E. B. Köksoy, Hilal Özakıncı, S. Hayme, Y. Urun, S. Sak, A. Demirkazık, G. Utkan","doi":"10.37047/JOS.2020-79248","DOIUrl":"https://doi.org/10.37047/JOS.2020-79248","url":null,"abstract":"EGFR is an important therapeutic target in lung adenocarcinoma.4 Oral tyrosine kinase inhibitors (TKIs) can be used in patients with driver mutations in EGFR.5 EGFR mutations were observed in ~1015% of NSCLC patients in Western populations and up to 50% in Asian populations.6,7 In a previous study, the EGFR mutation rate in adenocarcinomas was 33.9% for women and 9.4% for men in 499 cases, and the overall mutation rate was 14%.8 Also, EGFR mutations are more frequently detected in female patients and non-smokers.9","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"7 1","pages":"20-24"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69819061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
34 Marginal zone lymphomas (MZL) constitute around 10% of non-Hodgkins lymphomas. Extranodal marginal zone lymphoma (EMZL) is the most common form of MZL, constituting more than 70% of all MZL cases.1 Marginal zone lymphoma can be considered as a prototype of an antigen-driven tumor and has many microorganisms and autoimmune diseases associated with its pathogenesis.2 A pooled analysis of a series of trials showed that Sjögren’s Syndrome could increase the risk of MZL and EMZL of the parotid gland to 30 and 1000-folds, respectively. A similar association was also reported with systemic lupus erythematosus.3 The main causative infectious agents of the EMZL that were also associated with the specific disease locations were Helicobacter pylori, Chlamydia psittaci, Campylobacter jejuni, Borrelia burgdorferi, and Achromobacter xylosoxidans.4
{"title":"Same Disease, Different Approaches: A Report on Six Lymphoma Cases with Extranodal Marginal Zones in Rare Sites","authors":"Metin Demir, D. Guven, S. Kılıçkap","doi":"10.37047/JOS.2020-79452","DOIUrl":"https://doi.org/10.37047/JOS.2020-79452","url":null,"abstract":"34 Marginal zone lymphomas (MZL) constitute around 10% of non-Hodgkins lymphomas. Extranodal marginal zone lymphoma (EMZL) is the most common form of MZL, constituting more than 70% of all MZL cases.1 Marginal zone lymphoma can be considered as a prototype of an antigen-driven tumor and has many microorganisms and autoimmune diseases associated with its pathogenesis.2 A pooled analysis of a series of trials showed that Sjögren’s Syndrome could increase the risk of MZL and EMZL of the parotid gland to 30 and 1000-folds, respectively. A similar association was also reported with systemic lupus erythematosus.3 The main causative infectious agents of the EMZL that were also associated with the specific disease locations were Helicobacter pylori, Chlamydia psittaci, Campylobacter jejuni, Borrelia burgdorferi, and Achromobacter xylosoxidans.4","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"7 1","pages":"34-38"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69819552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ş. Gündüz, D. Erdem, D. Güven, S. Aksoy, M. Uysal, A. Kargi, A. Yıldız, I. Karaman, M. Özdoğan
85 Breast cancer is the most frequent diagnosis encountered in oncology clinics and the second cause of cancer-related mortality besides lung cancer among women worldwide.1 Although the methods of early detection have evolved, around 6% of women are still diagnosed with metastatic breast cancer at their first visit. In addition, as many as 30% of patients with non-metastatic early stage breast cancer will be diagnosed with distant metastatic disease during their disease course.2 Although there is currently no cure for metastatic breast cancer, newer systemic therapies have improved survival. Ixabepilone is an epothilone, a class of nontaxane microtubule-stabilizing agents that have activity in taxane-resistant patients. Many trials have demonstrated the efficacy of ixabepilone in chemotherapy-resistant tumors.3-5 This study assessed the efficacy of ixabepilone and compared two regimens of this drug in patients with metastatic breast cancer in daily clinical practice. Ixabepilone in Metastatic Breast Cancer: Real-World Experience
{"title":"Ixabepilone in Metastatic Breast Cancer: Real-World Experience","authors":"Ş. Gündüz, D. Erdem, D. Güven, S. Aksoy, M. Uysal, A. Kargi, A. Yıldız, I. Karaman, M. Özdoğan","doi":"10.37047/jos.2021-81340","DOIUrl":"https://doi.org/10.37047/jos.2021-81340","url":null,"abstract":"85 Breast cancer is the most frequent diagnosis encountered in oncology clinics and the second cause of cancer-related mortality besides lung cancer among women worldwide.1 Although the methods of early detection have evolved, around 6% of women are still diagnosed with metastatic breast cancer at their first visit. In addition, as many as 30% of patients with non-metastatic early stage breast cancer will be diagnosed with distant metastatic disease during their disease course.2 Although there is currently no cure for metastatic breast cancer, newer systemic therapies have improved survival. Ixabepilone is an epothilone, a class of nontaxane microtubule-stabilizing agents that have activity in taxane-resistant patients. Many trials have demonstrated the efficacy of ixabepilone in chemotherapy-resistant tumors.3-5 This study assessed the efficacy of ixabepilone and compared two regimens of this drug in patients with metastatic breast cancer in daily clinical practice. Ixabepilone in Metastatic Breast Cancer: Real-World Experience","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69819813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. Sönmez, A. Aytekin, R. Erten, M. Aldemir, A. Sakin, R. Esen
neoplasms identified simultaneously or within 6 months after the initial diagnosis in the same patient.1 However, synchronous tumors of the gastric and rectum carcinoma are not infrequent; particularly in the elderly male patient.2 The most commonly detected synchronous tumors in patients with gastric cancer are colorectal cancers, which are followed by lung, esophagus, and liver cancers.2 Rectal carcinoma commonly metastasizes to the liver, lungs, bone, brain, and lymph nodes.3 Esophageal metastasis of rectal carcinoma is an unusual occurrence owing to its rarity and challenges in diagnosis. Therefore, patients might be misdiagnosed sometimes and not be treated properly. Secondary carcinoma of the esophagus occurs as a result of the direct invasion, hematogenous, or lymphatic spread from the distant primary sites.4 Approximately 3.1-6.1% of patients who had died from any type of cancer in the autopsy series reported esophageal metastasis. Additionally, it has shown that the most common primary malignancies that metastasize to the esophagus are breast and lung cancers in the same autopsy series.3,5 Herein, we present the case of a 63-year-old man with synchronous gastric, rectal carcinoma, and in situ esophageal carcinoma who also had isolated esophageal metastasis from rectal carcinoma. J Oncol Sci. 2021;7(3):159-62
{"title":"Multiple Primary Synchronous Gastric, Esophageal, and Rectal Cancer and Isolated Esophageal Metastasis from Rectal Cancer: Case Report","authors":"G. Sönmez, A. Aytekin, R. Erten, M. Aldemir, A. Sakin, R. Esen","doi":"10.37047/jos.2020-80507","DOIUrl":"https://doi.org/10.37047/jos.2020-80507","url":null,"abstract":"neoplasms identified simultaneously or within 6 months after the initial diagnosis in the same patient.1 However, synchronous tumors of the gastric and rectum carcinoma are not infrequent; particularly in the elderly male patient.2 The most commonly detected synchronous tumors in patients with gastric cancer are colorectal cancers, which are followed by lung, esophagus, and liver cancers.2 Rectal carcinoma commonly metastasizes to the liver, lungs, bone, brain, and lymph nodes.3 Esophageal metastasis of rectal carcinoma is an unusual occurrence owing to its rarity and challenges in diagnosis. Therefore, patients might be misdiagnosed sometimes and not be treated properly. Secondary carcinoma of the esophagus occurs as a result of the direct invasion, hematogenous, or lymphatic spread from the distant primary sites.4 Approximately 3.1-6.1% of patients who had died from any type of cancer in the autopsy series reported esophageal metastasis. Additionally, it has shown that the most common primary malignancies that metastasize to the esophagus are breast and lung cancers in the same autopsy series.3,5 Herein, we present the case of a 63-year-old man with synchronous gastric, rectal carcinoma, and in situ esophageal carcinoma who also had isolated esophageal metastasis from rectal carcinoma. J Oncol Sci. 2021;7(3):159-62","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69819835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
91 One in 8 women in the community are predisposed to develop breast cancer, and this risk significantly escalates in women with a family history of breast carcinoma.1,2 Approximately, 10% of breast cancers are hereditary, and mutation in the breast cancer (BRCA) gene is one of the best-known mutations associated with breast cancer.2-5 The factors that increase the chances of a BRCA mutation in breast cancer include young age (<40 years), triple-negative tumors, male gender, family history, ovarian cancer, and bilateral breast cancer.6 Currently, BRCA mutations are evaluated in 2 subgroups, BRCA1 and BRCA2, and patients with BRCA mutations can develop secondary malignancies.
{"title":"Comparison of Clinicopathological Characteristics of BRCA1 and BRCA2 Carriers with Breast Cancer: The Role of Ki-67 Index","authors":"Recep Ak, C. Karaçin, T. Bahşi, Ö. B. Öksüzoğlu","doi":"10.37047/jos.2021-81821","DOIUrl":"https://doi.org/10.37047/jos.2021-81821","url":null,"abstract":"91 One in 8 women in the community are predisposed to develop breast cancer, and this risk significantly escalates in women with a family history of breast carcinoma.1,2 Approximately, 10% of breast cancers are hereditary, and mutation in the breast cancer (BRCA) gene is one of the best-known mutations associated with breast cancer.2-5 The factors that increase the chances of a BRCA mutation in breast cancer include young age (<40 years), triple-negative tumors, male gender, family history, ovarian cancer, and bilateral breast cancer.6 Currently, BRCA mutations are evaluated in 2 subgroups, BRCA1 and BRCA2, and patients with BRCA mutations can develop secondary malignancies.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69819879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Baran Akagunduz, D. Guven, M. Atçı, I. Cil, C. Karaçin, Muhammet Ozer, S. Kılıçkap
cer patients is 70 years and above.1 Recently, the rising life expectancy in the general population coupled with a disproportionate cancer burden among individuals aged 70 years and older have enthralled considerable interest in ensuring improved cancer treatment for the geriatric population.2 Significant limitation persists regarding optimal cancer treatment for older patients. Unique challenges are witnessed in the management of geriatric cancer patients. A thorough examination of the older person’s health status can aid in the assessment of risks and benefits of cancer treatment, affect the choice and intensity of treatment, and guide supportive care strategies.3 The central domains of geriatric assessment (GA) include physical and cognitive function assessment, comorbid medical problems, diet, medications, and psychological conditions.4 Despite the recommendations of the International Society of Geriatric Oncology (SIOG) and the National Comprehensive Cancer Network (NCCN), time restrictions mostly impede the systematic implementation of the application of geriatric assessment in oncology practice.5,6 To collect data without the time commitment and stress on patients and caregivers, cancer-specific geriatric evaluation tools have been designed.7 Nevertheless, the implementation of geriatric evaluation in daily medical oncology practice remains elusive.
{"title":"Determining the Current Situation of Geriatric Oncology in Turkey: A Survey of Medical Oncologists","authors":"Baran Akagunduz, D. Guven, M. Atçı, I. Cil, C. Karaçin, Muhammet Ozer, S. Kılıçkap","doi":"10.37047/JOS.2020-80824","DOIUrl":"https://doi.org/10.37047/JOS.2020-80824","url":null,"abstract":"cer patients is 70 years and above.1 Recently, the rising life expectancy in the general population coupled with a disproportionate cancer burden among individuals aged 70 years and older have enthralled considerable interest in ensuring improved cancer treatment for the geriatric population.2 Significant limitation persists regarding optimal cancer treatment for older patients. Unique challenges are witnessed in the management of geriatric cancer patients. A thorough examination of the older person’s health status can aid in the assessment of risks and benefits of cancer treatment, affect the choice and intensity of treatment, and guide supportive care strategies.3 The central domains of geriatric assessment (GA) include physical and cognitive function assessment, comorbid medical problems, diet, medications, and psychological conditions.4 Despite the recommendations of the International Society of Geriatric Oncology (SIOG) and the National Comprehensive Cancer Network (NCCN), time restrictions mostly impede the systematic implementation of the application of geriatric assessment in oncology practice.5,6 To collect data without the time commitment and stress on patients and caregivers, cancer-specific geriatric evaluation tools have been designed.7 Nevertheless, the implementation of geriatric evaluation in daily medical oncology practice remains elusive.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"7 1","pages":"25-30"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69819894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：